Acute Promyelocytic Leukemia (PML-RARA) · Gemtuzumab ozogamicin for relapsed APL with maintenance
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Track | aggressive |
|---|---|
| Linked regimen | REG-GEMTUZUMAB-APL |
| ID | IND-APL-RELAPSED-GEMTUZUMAB |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-APL |
| Sources | SRC-APL-RELAPSE-LENGFELDER-2017 SRC-MYLOFRANCE-ARIBI-2007 SRC-NCCN-AML-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L for relapsed APL post 1L ATRA + ATO OR multiply-relapsed. Ukraine access constraint for gemtuzumab dominant. AutoSCT consolidation for fit molecularly-CR.
Used By
Algorithms
ALGO-APL-2L- ALGO-APL-2L